Adjuvants designed for veterinary and human vaccines

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2666-2672

  Aucouturier, J ^a   Dupuis, L ^a   Ganne, V ^a  

^a Seppic 75 ^*  (France)

Author keywords

Adjuvants; Emulsions; Nanoparticles

Indexed keywords

ANTIGEN; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; MINERAL OIL; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; VACCINE; VETERINARY DRUG; WATER;

ANTIGEN PURIFICATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG QUALITY; DRUG SAFETY; DRUG SCREENING; EMULSION; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INOCULATION; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; EMULSIONS; HUMANS; MICROSPHERES; OILS; QUALITY CONTROL; SAFETY; VACCINES; VETERINARY DRUGS; WATER;

EID: 0035925593     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00498-9     Document Type: Article

References (51)

1. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de sérum antidiphtérique
2. A compendium of vaccine adjuvants and excipients. Vaccine design
3. Adjuvants - A classification and review of their modes of action
4. Adjuvants: Current status, clinical perspectives and future prospects
5. Les vaccins en emulsion dans les corps gras ou lipovaccins
6. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil
7. Classical and new approaches to adjuvant use in domestic food animals
8. Formulation concepts for the emulsion maker
9. Emulsions and emulsion technology, part III
10. Prolonged release of drug from O/w emulsion and residence in rat nasal cavity
11. The mode of action of immunological adjuvants
12. Mechanism of adjuvant activity
13. Adjuvants and immune regulation by lymphoid cells
14. Function of carriers and adjuvants in induction of immune responses
15. Enhancement of the efficacy of a replication-defective adenovirus-vectored vaccine by the addition of oil adjuvants
16. New metabolizable immunologic adjuvant for human use: I, development and animal immune response
17. Immunomodifiers in vaccines
18. Vaccine adjuvants
19. Metabolic fate of mineral oil adjuvants using 14C-labeled tracers I: Mineral oil
20. Immunosuppressive effect in mycobacterial adjuvant emulsions of mineral oils containing low molecular weight hydrocarbons
21. The toxicity of free fatty acids and arlacel A
22. Muramyl dipeptide and derivatives
23. Freund type mineral oil adjuvant emulsions
24. Oil adjuvant vaccine against foot-and-mouth disease
25. Technical aspects of the administration of vaccines
26. Assessment of oil adjuvants in newcastle disease vaccine
27. The inactived Cowdria ruminantium vaccine for heartwater protects against heterologous strains and against laboratory and field tick challenge
28. Analysis of peripheral blood mononuclear cell population in cattle and goats immunized with killed Cowdria ruminantum in oil adjuvant by flow cytometry
29. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (MONTANIDE ISA 720)
30. Multiple emulsions: A new form of mineral oil antigen adjuvants
31. Emergency vaccination of pigs against foot-and-mouth disease: Protection against disease and reduction in contact transmission
32. Immunity conferred by oil adjuvant haemorrhagic septicaemia vaccine
33. New safe and efficient oil adjuvants for veterinary vaccines
34. International bank for foot-and-mouth disease vaccine: Assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants
35. The use of adjuvants with gX deleted pseudorabies virus vaccines
36. Oils adjuvants enhance the potency of vectored or DNA vaccines expressing the pseudorabies virus glycoprotein gp50 gene
37. Efficacy and safety of new adjuvanted vaccine formulations containing inactivated exotoxin antigens from Pasteurella multocida
38. Assessment of a new adjuvant range in a model for atrophic rhinitis
39. Clinical and humoral immune responses of cattle vaccinated with an experimental inactivated Anaplasma marginale vaccine in 2 different adjuvants
40. Aluminium adjuvants
41. Effect of adjuvants on vaccination or human beings against influenza
42. Use of adjuvants in studies on influenza immunisation. Degree of persistence of antibody in human subjects two years after vaccination
43. Follow-up study on army personnel who received adjuvant influenza virus vaccine 1951-1953
44. Long-term mortality follow-up of army recruits who received adjuvant influenza virus vaccine 1951-1953
45. Long term follow-up of army recruits immunised with Freund's incomplete adjuvanted vaccine
46. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: Results of a double-blind, adjuvant-controlled, dose-ranging trial
47. Clinical and immunologic effects of a synthetic β-human chorionic gonadotropin vaccine
48. Novel adjuvants currently in clinical testing November 2-4, 1998, fondation mérieux, annecy, france: A meeting sponsored by the world health organization
49. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720
50. Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides